New drug combo for advanced nasopharyngeal cancer after platinum failure
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of three drugs—an anti-PD1 immunotherapy, nimotuzumab (targets EGFR), and capecitabine (chemotherapy)—for people whose nasopharyngeal cancer has returned or spread and no longer responds to platinum-based chemotherapy. The goal is to see if this combination can help when standard treatment stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nasopharyngeal cancer that has come back or spread to other parts of the body and cannot be cured with surgery or radiation.
- You have already received platinum chemotherapy for your advanced cancer and it either did not work or stopped working.
- You are between 18 and 75 years old.
- You are in generally good health (able to do daily activities, like walking) and have a life expectancy of at least 3 months.
- You have at least one tumor that can be measured on scans.
- Your blood counts, liver and kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding targeted radiotherapy (SBRT) to PD-1 immunotherapy plus capecitabine can improve outcomes for people with newly diagnosed metastatic nasopharyngeal cancer. You may be eligible if your cancer has responded at least to “stable disease” after an initial chemo-immunotherapy course.
This Phase 3 trial compares different chemotherapy drugs given along with radiation therapy for people with locally advanced nasopharyngeal cancer. It aims to find which drug approach works better and is safer for this stage of disease.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This trial tests a combination of three drugs (MRG003, capecitabine, and a PD-1 inhibitor) for nasopharyngeal cancer that has come back only in the same area. The goal is to see if this combination can shrink the tumor and prevent it from coming back.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
This trial tests a combination of chemotherapy with two additional drugs (nimotuzumab and toripalimab) for people with advanced nasopharyngeal cancer that hasn't been treated yet. The goal is to see if this mix works better than standard therapy.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.